ArticleClinical drug investigation2022

Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.

Tadesse M Abegaz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.